In der neuesten Ausgabe der Dermatology Times wird mal wieder Alemuz erwähnt. Bloß diesmal bereits im Zusammenhang mit Akne. Folgende Abschnitte gefallen mir besonders gut:
"Acne affects up to 50 million Americans annually,"
"FUTURE OF ACNE TREATMENT
According to Future Market Insights Moderate-to-Severe Acne Therapeutics Market Report, growing prevalence of moderate-to-severe acne over the globe is expected to generate high demand for new treatments. The report explains that increasing adoption of innovative acne treatment therapies,
such as photodynamic therapy and laser therapy has led to further revenue generation in the acne market. However, the safety issues associated with the anti-acne drugs such as complications
in pregnancy and the adverse effects of retinoids such as skin irritation and dryness, restrain the moderate-to-severe acne therapeutics market growth.
“Acne affects Americans of all ages and backgrounds, and like so many patients, those with acne have varying treatment needs,” says Humphries. “We believe that the development of treatments for this condition will continue to increase and improve in the future, which we hope will ultimately result in better health and quality of life for all patients.”"
....hat aber natürlich alles nix mit der Bewertung von Biofrontera zu tun
